search

Active clinical trials for "Osteoporosis, Postmenopausal"

Results 181-190 of 295

Mediterranean Diet for Post-menopausal Women: Effects on Bone Turnover

OsteoporosisPostmenopausal Bone Loss

The investigators propose a 24 week clinical research trial (12 week observational period followed by 12 week MedSD intervention) with feasibility of diet adoption and markers of bone turnover as the primary outcomes.

Completed12 enrollment criteria

A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered...

OsteoporosisPostmenopausal

This study is a Phase 1, multi-center, 2-part, subject- and investigator-blind, randomized, placebo-controlled, multiple dose study of transdermal teriparatide (80-µg dose) in healthy postmenopausal women. Part A will examine the cumulative irritation and adherence of the transdermal patch, and Part B will examine skin sensitization and adherence. Two separate groups of subjects will be enrolled for Part A and Part B of the study. All screening procedures will take place up to 28 days prior to enrollment.

Completed36 enrollment criteria

A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis

OsteoporosisPostmenopausal

The study in the labeled and real conditions of prescription of Actonel will investigate the satisfaction of patients with its new formulation: 35 mg Once A Week. The study will also measure response rates in CTX (the C-telopeptide of type I collagen) at baseline and after 12 weeks of treatment with risedronate 35 mg Once A Week.

Completed4 enrollment criteria

A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly...

Post Menopausal Osteoporosis

This study will determine the rapidity of suppression of the bone resorption marker sCTX in post-menopausal women with osteoporosis.Other bone turnover markers will also be evaluated. Patients will be randomised to either monthly Boniva 150mg or placebo, in combination with vitamin D and calcium supplementation. The anticipated time on study treatment is approximately 7 months, and the target sample size is <100 individuals.

Completed9 enrollment criteria

A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)...

OsteoporosisPostmenopausal

The purpose of this study is to compare how well alendronate and raloxifene increase the bone density in women who have osteoporosis and have experienced menopause.

Completed6 enrollment criteria

A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

OsteoporosisPostmenopausal

The purpose of this study is to evaluate the tolerability of two different formulations of blosozumab in women who have reached menopause. This study will last approximately 12 weeks for each participant, not including screening. Screening is required within 28 days prior to starting the study.

Terminated8 enrollment criteria

Quercetin's Effect on Bone Health and Inflammatory Markers

OsteoporosisPostmenopausal

Quercetin is a plant-based flavonoid that is naturally found in many fruits and vegetables, and is considered to be a potent antioxidant with several expected health benefits such as anti-inflammatory effects and bone-conserving properties. Participants will supplement with either Quercetin, or placebo, for 90-days with pre- and post-testing visits.

Completed22 enrollment criteria

Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis

OsteoporosisPostmenopausal1 more

Symptoms of periodontal disease are tissue destruction and destruction of the alveolar bone which supports the tooth. Wnt way (wingless-type MMTV integration site family) plays a role in the regulation of bone homeostasis in periodontal disease-induced bone resorption. The Wnt / β-catenin signal is controlled by physiological antagonists, including dickkopf released from osteocytes-associated protein 1 (DKK-1) and sclerostin (SOST). Thus, Wnt inhibitors SOST and DKK-1 affect bone mass changes. Bisphosphonates used in osteoporous treatment are selective inhibitors of bone resorption. In the serum of postmenopausal osteoporotic women treated with bisphosphonate, short-term and decreased DKK-1 level during the treatment, and increased SOST in the late period were reported. Increased bone formation after bisphosphonate treatment in postmenopausal osteoporotic patients has been associated with increased serum SOST level. The aim of our study is to investigate the effect of bisphosphonate in patients with post-menopausal osteoporosis on the bone demolition metabolism in periodontally healthy and periodontally diseased tooth regions and gingival health with the clinical data by investigating the SOST and DDK-1 molecules that play role in bone destruction mechanism.

Completed7 enrollment criteria

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)...

OsteoporosisPostmenopausal Osteoporosis

This study will evaluate the therapeutic effects and safety of odanacatib on bone mineral density in osteoporotic postmenopausal women who were previously treated with alendronate.

Withdrawn13 enrollment criteria

ValoRization of Dairy Sidestreams to Fight Calcium dEficits iN Postmenopausal Women

OsteoporosisPostmenopausal

The primary objective of this study is to investigate the effects of 12-months supplementation with calcium-enriched permeate, taken alone or in conjunction with inulin, on changes in markers of bone formation and resorption and in bone mass density (BMD) in apparently healthy postmenopausal women compared with calcium-carbonate or maltodextrin supplementation.

Completed17 enrollment criteria
1...181920...30

Need Help? Contact our team!


We'll reach out to this number within 24 hrs